TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

24 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    PET Imaging Evaluation of [11C]SY08

    Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s

    📍 MGH · Charlestown, MA · Get directions →

    The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Lupus (SLE)

    A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

    Testing enpatoran over 24 weeks for skin lupus symptoms, with or without whole-body disease

    📍 Inland Rheumatology Clinical Trials, Inc. · Upland, CA · +7 more US sites · Get directions →

    The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Parkinson's disease

    Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

    Testing an injection for brain scans to study Parkinson’s disease and safety

    📍 Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT · Get directions →

    This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Parkinson's disease

    A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    Testing a Parkinson’s surgery approach to see if it is safe and works

    📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →

    Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

    ✓ Study care freePhase 3Ages 45–75Learn more →
  • Parkinson's disease

    Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

    Testing a new PET brain scan to measure nerve protein buildup in Parkinson’s

    📍 Invicro (dba Perceptive) · New Haven, CT · +1 more US site · Get directions →

    This clinical study is being conducted to learn more about a new imaging drug called \[18F\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Lupus (SLE)

    📍 Pinnacle Research Group Llc · Anniston, AL · +20 more US sites · Get directions →

    The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

    ✓ Study care freePhase 3Ages 12–100Learn more →
  • Lupus (SLE)

    Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

    Testing what happens to older people with lupus if they stop their hydroxychloroquine

    📍 University of California, Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use.

    ✓ Study care freePhase 3Ages 60+Learn more →
  • Parkinson's disease

    18F-DOPA II - PET Imaging Optimization

    Testing an imaging scan to study Parkinson’s disease using PET

    📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →

    A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.

    ✓ Study care freePhase 3Learn more →
  • Lupus (SLE)

    A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

    Testing whether cenerimod added to usual treatment helps adults with active lupus nephritis

    💵 May compensate

    📍 Alloy Clinical Research LLC · Kissimmee, FL · +10 more US sites · Get directions →

    The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Parkinson's disease

    Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

    Studying how a brain imaging tracer binds in early Parkinson’s over 24 months

    📍 UAB · Birmingham, AL · Get directions →

    The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers.

    ✓ Study care freeEarly Phase 1Ages 18–99Learn more →
  • Lupus (SLE)

    A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

    Testing a treatment called enpatoran for skin lupus symptoms over 24 weeks

    📍 Dermatology Research Associates - 300204025 · Los Angeles, CA · +10 more US sites · Get directions →

    The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Lupus (SLE)

    An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

    Testing an IV medicine to study effects and safety in children with lupus

    📍 Research Site · Phoenix, AZ · +21 more US sites · Get directions →

    A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

    ✓ Study care freePhase 3Ages 5–17Learn more →
  • Lupus (SLE)

    Safety and Efficacy of ONT01 in Lupus

    Studying whether ONT01 is safe and tolerated in people with lupus

    📍 Hospital for Special Surgery · New York, NY · Get directions →

    ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE.

    ✓ Study care freeEarly Phase 1Ages 18+Learn more →
  • Parkinson's disease

    A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    Testing an IV drug in people with early-stage Parkinson’s disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

    ✓ Study care freePhase 3Ages 50–85Learn more →
  • Lupus (SLE)

    📍 Sl0044 50058 · Avondale, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

    ✓ Study care freePhase 3Ages 16+Learn more →
  • Parkinson's disease

    Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)

    Testing an 8-week exercise program with boxing and computer games for people with Parkinson disease

    📍 Equilibrium Physical Therapy · Ventura, CA · Get directions →

    In this pilot study the research will explore whether exercises and the outcome measures would be acceptable to conduct a more detailed research study. This 8 week pilot study will utilize a comprehensive exercise program that includes non-contact boxing along with computerized games for individuals with Parkinson Disease.

    ✓ Study care freeEarly Phase 1Ages 40–80Learn more →
  • Parkinson's disease

    Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease

    Testing whether automatic speech recognition feedback improves speech clarity and social

    📍 Teachers College, Columbia University · New York, NY · Get directions →

    The goal of this clinical trial is to learn whether noise-augmented feedback using automatic speech recognition improves intelligibility and social participation in individuals with Parkinson's disease. The main questions the investigators will address are: Does noise-augmented feedback lead to increased intelligibility, as measured by transcription accuracy scores?

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Parkinson's disease

    A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

    Testing a wearable sensor to track swallowing and drooling problems in people with Parkinson’s

    📍 Northwestern University · Evanston, IL · Get directions →

    The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.

    ✓ Study care freePhase 3Ages 22+Learn more →
  • Lupus (SLE)

    Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

    Testing how well and how safe a medicine is for lupus nephritis after stopping study treatment

    📍 Novartis Investigative Site · Salvador, Estado de Bahia · Get directions →

    The purpose of this 2-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response \[CRR\] or partial renal response \[PRR\]) on double-blind treatment at the end of the SIRIUS-LN core study, and 2.

    ✓ Study care freePhase 3Ages 18–100Learn more →
  • Lupus (SLE)

    A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

    Studying how well a weekly under-the-skin injection helps lupus symptoms in people who are new to

    📍 Research Site · Anniston, AL · +28 more US sites · Get directions →

    The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Lupus (SLE)

    A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

    Testing whether nipocalimab works better than placebo for lupus in adults

    📍 David S Hallegua MD A Professional Corporation · Beverly Hills, CA · +28 more US sites · Get directions →

    The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Parkinson's disease

    Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

    Testing how scans after deep brain stimulation help assess Parkinson’s gait

    📍 University of Minnesota · Minneapolis, MN · Get directions →

    Sixty patients will be enrolled in this study who are treated for Parkinson's disease (PD) with bilateral deep brain stimulation of subthalamic nucleus (STN) or globus pallidus (GP), who have a pre- operative 7 Tesla MRI including diffusion tensor imaging for tractography and a postoperative head CT for electrode localization, and in whom at least 3 months have passed since activation of their neurostimulators, for stabilization of clinical stimulator settings. Using their MRI and CT, the investigators will construct patient-specific models of electrical current spread to neuroanatomical tar- gets surrounding the electrode.

    ✓ Study care freeEarly Phase 1Ages 18–89Learn more →
  • Parkinson's disease

    A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    Testing BHV-8000 for safety and effectiveness in adults with early Parkinson's disease

    📍 Site-049 · Birmingham, AL · +14 more US sites · Get directions →

    A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

    ✓ Study care freePhase 2Ages 40–85Learn more →